<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0111234414
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EZEACT 40 mg Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AZILSARTAN MEDOXOMIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        65.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TAKEDA PHARMACEUTICAL COMPANY LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TAKEDA PHARMACEUTICAL COMPANY LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 651]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACEUTICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACETICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ezeact contains an active substance called azilsartan medoxomil and belongs to a class of medicines<br />called angiotensin II receptor antagonists (AIIRAs). Angiotensin II is a substance which occurs<br />naturally in the body and which causes the blood vessels to tighten, therefore increasing your blood<br />pressure. Ezeact blocks this effect so that the blood vessels relax, which helps lower your blood<br />pressure.<br />This medicine is used for treating high blood pressure (essential hypertension) in adult patients (over<br />18 years of age).<br />A reduction in your blood pressure will be measureable within 2 weeks of initiation of treatment and<br />the full effect of your dose will be observed by 4 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do NOT take Ezeact if you<br />- are allergic to azilsartan medoxomil or any of the other ingredients of this medicine (listed in<br />section 6).<br />- are more than 3 months pregnant. (It is also better to avoid this medicine in early<br />pregnancy - see pregnancy section).<br />- have diabetes or impaired kidney function and you are treated with a blood pressure lowering<br />medicine containing aliskiren.<br />Warnings and precautions<br />Talk to your doctor before taking Ezeact, especially if you<br />- have kidney problems.<br />- are on dialysis or had a recent kidney transplant.<br />- have severe liver disease.</p><p>- have heart problems (including heart failure, recent heart attack).<br />- have ever had a stroke.<br />- have low blood pressure or feel dizzy or lightheaded.<br />- are vomiting, have recently had severe vomiting, or have diarrhoea.<br />- have raised levels of potassium in your blood (as shown in blood tests).<br />- have a disease of the adrenal gland called primary hyperaldosteronism.<br />- have been told that you have a narrowing of the valves in your heart (called &ldquo;aortic or mitral<br />valve stenosis&rdquo;) or that the thickness of your heart muscle is abnormally increased (called<br />&ldquo;obstructive hypertrophic cardiomyopathy&rdquo;).<br />- are taking any of the following medicines used to treat high blood pressure:<br />o an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have<br />diabetes-related kidney problems.<br />o aliskiren.<br />- are concomitantly using Ezeact with renin-angiotensin system blockers as it may be<br />associated with serious adverse reactions such as kidney problems and high potassium levels<br />in the blood<br />Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g.<br />potassium) in your blood at regular intervals.<br />See also information under the heading &ldquo;Do not take Ezeact&rdquo;.<br />You must tell your doctor if you think you are (or might become) pregnant. Ezeact is not<br />recommended in early pregnancy, and must NOT be taken if you are more than 3 months pregnant, as<br />it may cause serious harm to your baby if used at that stage (see section &quot;Pregnancy section and<br />breast-feeding&quot;). Ezeact may be less effective in lowering the blood pressure in black patients.<br />Children and adolescents<br />There is limited data on the use of Ezeact in children or adolescents under 18 years of age. Therefore,<br />this medicine should not be given to children or adolescents.<br />Other medicines and Ezeact<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines.<br />Ezeact can affect the way some other medicines work and some medicines can have an effect on<br />Ezeact.<br />In particular, tell your doctor if you are taking any of the following medicines:<br />- Lithium (a medicine for mental health problems)<br />- Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac or celecoxib<br />(medicines to relieve pain and inflammation)<br />- Acetylsalicyclic acid if taking more than 3 g per day (medicine to relieve pain and<br />inflammation)<br />- Medicines that increase the amount of potassium in your blood; these include potassium<br />supplements, potassium-sparing medicines (certain &lsquo;water tablets&rsquo;) or salt substitutes<br />containing potassium<br />- Heparin (a medicine for thinning the blood)<br />- Diuretics (water tablets)<br />- Aliskiren or other medicines to lower your blood pressure (angiotensin converting enzyme<br />inhibitor or angiotensin II receptor blocker, such as enalapril, lisinopril, ramipril or valsartan,<br />telmisartan, irbesartan).<br />Your doctor may need to change your dose and/or to take other precautions if you are taking an<br />ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do not take Ezeact&rdquo; and<br />&ldquo;Warnings and precautions&rdquo;).</p><p>Pregnancy and breast-feeding<br />Pregnancy</p><p>You must tell your doctor if you think you are (ormight<br />Breast-feeding<br />Tell your doctor if you are breast-feeding. Ezeact is not recommended for mothers who are breastfeeding,<br />and your doctor may choose another treatment for you if you wish to breast-feed, especially<br />if your baby is newborn, or was born prematurely.<br />Driving and using machines<br />Ezeact is unlikely to have an effect on driving or using machines. However some people may feel<br />tired or dizzy when taking this medicine and if this happens to you, do not drive or use any tools or<br />machines.<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>3. How to take Ezeact<br />Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist<br />if you are not sure. It is important to keep taking Ezeact every day at the same time.<br />Ezeact is for oral use. Take the tablet with plenty of<br />water. You can take this medicine with or without food.<br />- The usual starting dose is 40 mg once a day. Your doctor may increase this dose to a maximum of 80<br />mg once a day depending on blood pressure response.<br />- If you suffer from other coexisting illnesses such as severe kidney disease or heart failure your doctor<br />will decide on the most appropriate starting dose.<br />A reduction in your blood pressure will be measureable within 2 weeks of initiation of treatment and the<br />full effect of your dose will be observed by 4 weeks.<br />If you take more Ezeact than you should<br />If you take too many tablets, or if someone else takes your medicine, contact your doctor immediately.<br />You may feel faint or dizzy if you have taken more than you should.<br />If you forget to take Ezeact<br />Do not take a double dose to make up for a forgotten dose. Just take the next dose at the usual time.<br />If you stop taking Ezeact<br />If you stop taking Ezeact, your blood pressure may increase again. Therefore do not stop taking<br />Ezeact without first talking to your doctor about alternative treatment options.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />become) pregnant. Your doctor will<br />normallyadvise you to stop taking this medicine before you become pregnant or as soon as you know<br />you are pregnant and will advise you to take another medicine instead of Ezeact.<br />Ezeact is not recommended in early pregnancy, and must NOT be taken when more than 3 months<br />pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>Stop taking Ezeact and seek medical help immediately if you have any of the following allergic<br />reactions, which occur rarely (may affect up to 1 in 1,000 people):<br />- Difficulties in breathing, or swallowing, or swelling of the face, lips, tongue and/or<br />throat(angioedema)<br />- Itching of the skin with raised lumps.<br />Other possible side effects include:<br />Common side effects (may affect up to 1 in 10 people):<br />- Dizziness<br />- Diarrhoea<br />- Increased blood creatine phosphokinase (an indicator of muscle damage).<br />Uncommon side effects (may affect up to 1 in 100 people):<br />- Low blood pressure, which may make you feel faint or dizzy<br />- Feeling tired<br />- Swelling of the hands, ankles or feet (peripheral oedema)<br />- Skin rash and itching<br />- Nausea<br />- Muscle spasms<br />- Increased serum creatinine in the blood (an indicator of kidney function)<br />- Increased uric acid in the blood.<br />Rare side effects (may affect up to 1 in 1,000 people):<br />- Changes in blood test results including decreased levels of a protein in the red blood cells<br />(haemoglobin).<br />When Ezeact is taken with chlorthalidone (a water tablet), higher levels of certain chemicals<br />in the blood (such as creatinine), which are indicators of kidney function, have been seen<br />commonly (in less than 1 in 10 users), and low blood pressure is also common.<br />Swelling of the hands, ankles or feet is more common (in less than 1 in 10 users) when Ezeact is<br />taken with amlodipine (a calcium channel blocker for treating hypertension) than when Ezeact is<br />taken alone (less than 1 in 100 users). The frequency of this effect is highest when amlodipine is<br />taken alone.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects<br />not listed in this leaflet. You can also report side effects directly National Pharmacovigilance and<br />Drug Safety Centre (NPC) listed at the end of this leaflet. By reporting side effects you can help<br />provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30 &deg;C<br />Keep out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date<br />refers to the last day of the month.<br />Store Ezeact in the original package in order to protect it from light and moisture.<br />This medicine does not require any special temperature storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Ezeact contains<br />- The active substance is azilsartan medoxomil (as potassium).<br />Ezeact 40 mg: Each tablet contains 40 mg azilsartan medoxomil (as potassium)<br />Ezeact 80 mg: Each tablet contains 80 mg azilsartan medoxomil (as potassium)<br />- The other ingredients are mannitol, fumaric acid, sodium hydroxide, hydroxypropylcellulose,<br />croscarmellose sodium, microcrystalline cellulose, and magnesium stearate.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ezeact tablets is white to nearly white plain tablets debossed “ASL” on one side and either “40” or
“80” on the other side.
Ezeact is available in a pack size of 28 tablets (4 blisters each containing 7 tablets).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder, secondary packaging and final release site:<br />Batterjee Pharmaceutical Factory<br />Industrial Area-Phase-IV,<br />Jeddah-21443, Kingdom of Saudi Arabia</p><p>Manufacturer:<br />Takeda Pharmaceutical Company Limited,<br />17-85, Jusohonmachi, 2-chome<br />Osaka 532-8686, Japan</p><p>Primary packaging site:<br />AndersonBrecon Inc.<br />4545 Assembly Drive<br />Rockford IL 61109, USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي دواء إيزكت على مادة فعالة تسمى أزيلاسارتان ميدوكسوميل وهو أحد الأدوية التي تنتمي إلى فئة الأدوية المسماة مضادات مستقبلات<br />هي عبارة عن مادة تحدث في الجسم بشكل طبيعي وتتسبب في تضييق الأوعية الدموية مما يؤدي إلى ارتفاع II ومادة أنجيوتنسين .II أنجيوتنسين<br />ضغط الدم لديك. فيقوم دواء إيزكت بتثبيط هذا التأثير حتى تسترخي أوعيتك الدموية مما يساعد على تخفيضضغط الدم لديك.<br />ويستخدم هذا الدواء لمعالجة ضغط الدم المرتفع (فرط ضغط الدم الأساسي) في المرضى البالغين (ممن تكون أعمارهم فوق ١٨ عاما).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع الاستخدام:<br />- إذا كنت تعاني حساسية (حساسية مفرطة) من مادة أزيلاسارتان ميدوكسوميل أو أي من مكونات دواء إيزكت الأخرى (انظر الفقرة<br />.( رقم ٦<br />- إذا كنت حاملا لمدة تتجاوز ٣ أشهر. (كما يفضل تجنب دواء إيزكت في مراحل الحمل المبكرة &ndash; انظر فقرة الحمل).<br />- إذا كنت تعاني مرض السكري أو اعتلال في وظيفة الكلية وتخضع للعلاج باستخدام دواء مخفض لضغط الدم يحتوي على مادة<br />.(aliskiren) اليسكيرين<br />تحذيرات وتدابير وقائية<br />قبل أو أثناء تناولك دواء إيزكت يرجى إبلاغ الطبيب فيما إذا:<br />- كنت تعاني مشاكل في الكلى<br />- كنت تخضع للغسيل الكلوي أو قمت بعملية زراعة كلية مؤخرا<br />- كان لديك التهاب كبدي حاد<br />- كان لديك مشاكل قلبية (من ضمنها قصور القلب أو نوبة قلبية تعرضت لها مؤخرا)<br />- عانيت سكتة دماغية في حياتك<br />- تعاني انخفاض الضغط أو تشعر بالدوار أو الدوخة<br />- كنت تعاني التقيؤ أو عانيت تقيؤا حادا مؤخرا أو كنت تعاني الإسهال</p><p>&nbsp;</p><p>- كان جسمك يحتوي على مستويات مرتفعة من البوتاسيوم<br />- تعاني مرض الغدة الكظرية المسمى فرط الألدوستيرونية<br />- أبلغك الطبيب بأنك تعاني تضيق صماماتك القلبية (الذي يسمى &quot;تضيق الصمام الأبهري أو الصمام الميترالي&quot;) أو ازدياد في سماكة<br />عضلات القلب على نحو غير طبيعي (والذي يسمى &quot;اعتلال عضلة القلب التضخمي الانسدادي&quot;)<br />- كنت تتناول أيا من الأدوية التالية المستخدمة لعلاج ضغط الدم:<br />مثبط الأنزيم المحول للأنجيوتنسين (على سبيل المثال إنالابريل، ليسينوبريل، راميبريل) وعلى وجه الخصوص إذا كنت تعاني من o<br />مشاكل الكلى المتعلقة بمرضالسكري.<br />.(aliskiren) اليسكيرين o<br />إذا كنت تستخدم إیزكت بالتزامن مع حاصرات نظام الرینین-أنجیوتنسین ،حیث أنھ مرتبط بحدوث تفاعلات دوائیة ضارة تتسبب<br />بمشاكل بالكلى و ارتفاع نسب البوتاسیوم في الدم<br />-<br />وقد يقوم طبيبك بإجراء فحوصات دورية من آن لآخر لوظائف الكلى وضغط الدم وكمية الإلكتروليت (مثل البوتاسيوم) في جسمك.<br />انظر كذلك المعلومات المذكورة تحت عنوان &quot;موانع الاستخدام&quot;.<br />لابد لك من إبلاغ طبيبك إن كنت تظنين أنك حامل (أو تتوقعين وقوع الحمل). كما لا ينصح بدواء إيزكت في المراحل المبكرة من الحمل، تجنبي<br />تناوله إذا كان عمر حملك أكثر من ٣ أشهر فربما يتسبب في أذى بالغ لجنينك إذا استخدمتيه في تلك المرحلة (انظري الفقرة الخاصة بالحمل).<br />الأخرى فقد تكون مادة أزيلاسارتان ميدوكسوميل أقل فاعلية في تخفيض ضغط II كما هو الحال مع جميع أدوية مضادات مستقبلات أنجيوتنسين<br />الدم عند تناولها من قبل المرضى ذوي البشرة السوداء.<br />الأطفال والمراهقين<br />لم يخضع استخدام دواء إيزكت للأطفال والمراهقين ممن هم دون سن ١٨ عاما للتجربة. لذلك لا ينصح بإعطاء دواء إيزكت للأطفال والمراهقين.<br />دواء إيزكت مع الأدوية الأخرى<br />يرجى إبلاغ طبيبك أو الصيدلي فيما إذا كنت تتناول أو قد تناولت مؤخرا أي أدوية أخرى بما في ذلك الأدوية التي استخدمتها من تلقاء نفسك دون<br />وصفة طبية.<br />قد يؤثر دواء إيزكت في طريقة عمل بعضالأدوية الأخرى، كما يحتمل أن تؤثر بعضالأدوية في فاعلية دواء إيزكت.<br />أخبر طبيبك، إذا كنت تتناول أيا من الأدوية التالية على وجه الخصوص:<br />- ليثيوم (دواء يستعمل لعلاج المشاكل النفسية)<br />- مضادات التهاب لاستيرودية، مثل: إيبوبروفين، أو ديكلوفيناك، أو سيليكوكزيب (هي أدوية تعمل على تخفيف الآلام والالتهابات)<br />- الأسبيرين (حمضأسيتيل ساليسيليك) إذا كانت جرعته أكثر من ٣ جرام في اليوم (هو دواء لتسكين الآلام والالتهابات)<br />- الأدوية التي تزيد كمية البوتاسيوم في جسمك بما في ذلك مكملات البوتاسيوم، الأدوية الموفرة للبوتاسيوم (&quot;أقراص مياه&quot; معينة) أو<br />بدائل الأملاح التي تحتوي على البوتاسيوم.<br />- هيبارين (هو دواء مميع للدم)<br />- مدرات البول (أقراصمياه)<br />أو الأدوية الأخرى المستخدمة لتخفيض ضغط الدم (مثبط الأنزيم المحول للأنجيوتنسين أو مضاد مستقبلات (aliskiren) - اليسكيرين<br />منها: إنالابريل، ليسينوبريل، راميبريل أو فالسارتان، تيلميسارتان، إربيسارتان). ،II أنجيوتنسين<br />(aliskiren) قد يحتاج طبيبك إلى تغيير جرعتك و/أو اتخاذ تدابير وقائية أخرى إذا كنت تتناول مثبط الأنزيم المحول للأنجيوتنسين أو اليسكيرين<br />(اقرأ المعلومات المنصوص عليها تحت العنوانين: &quot;موانع الاستخدام&quot; و&quot;التحذيرات والتدابير الوقائية&quot;).<br />الحمل والرضاعة الطبيعية<br />الحمل<br />يجب أن تخبري طبيبك إن كنت تظنين أنك حامل (أو تتوقعين حدوث الحمل). حيث سيقوم طبيبك عادة بتقديم النصح لك بأن تتوقفي عن تناول<br />دواء إيزكت قبل الحدوث المحتمل للحمل أو بمجرد تيقنك بحدوث الحمل، كما سينصحك الطبيب بتناول دواء آخر عوضا عن دواء إيزكت.<br />لا ينصح بتناول دواء إيزكت في مراحل الحمل المبكرة ويحذر من تناوله عند مرور أكثر من ٣ أشهر على حملك فربما يتسبب في أذى بالغ<br />لجنينك إن استخدمتيه بعد الشهر الثالث من الحمل.<br />الرضاعة الطبيعية<br />أخبري طبيبك إن كنت تقومي بالرضاعة الطبيعية أو على وشك البدء فيها. إذ لا ينصح بدواء إيزكت للأمهات اللاتي يرضعن أبناءهن، وقد<br />يصف لك طبيبك علاجا بديلا إن كنت راغبة في الرضاعة الطبيعية وخصوصا إن كان طفلك مبتسرا أو حديث الولادة.<br />القيادة واستخدام الآلات<br />لا يرجح أن يكون لدواء إيزكت أي آثار جانبية عند القيادة أو إدارة الماكينات. وعلى أي حال فقد يشعر بعض الناس بالتعب أو الدوار عند تناوله،<br />إذا حدث ذلك فتوقف فورا عن: القيادة، واستخدام أي أدوات، وإدارة الماكينات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دواء إيزكت دائما طبقا للجرعة التي وصفها لك طبيبك بالضبط. وإن لم تكن متأكدا من الجرعة يتوجب عليك أن تسأل طبيبك أو الصيدلي.<br />كما تجدر الإشارة إلى أهمية تناولك دواء إيزكت يوميا.<br />يستخدم دواء إيزكت عن طريق الفم. وتناول الدواء مع كمية وافرة من الماء.<br />كما تستطيع أن تتناول دواء إيزكت مع الطعام أو من دونه.<br />- تبلغ الجرعة المعتادة في البداية ٤٠ ملجم مرة واحدة في اليوم. وقد يزيد طبيبك هذه الجرعة لتصل كحد أقصى إلى ٨٠ ملجم في اليوم<br />اعتمادا على استجابة ضغط الدم لديك.<br />- إن كنت تعاني أحد الأمراض المصاحبة، مثل: القصور الكلوي الحاد أو قصور القلب عندها سيقرر طبيبك أكثر جرعة تناسبك لتبدأ<br />بها.<br />- كما يمكن قياس انخفاضضغط دمك خلال أسبوعين من بدء العلاج ويمكن ملاحظة التأثير الكامل للجرعة التي تتناولها بعد ٤ أسابيع.<br />إذا تناولت جرعة زائدة من دواء إيزكت<br />إذا تناولت العديد من الأقراص أو قام شخص آخر بتناول دوائك، يرجى الاتصال بطبيبك على الفور. كما أنك قد تشعر بالإغماء أو الدوار إذا<br />تناولت جرعة أكثر مما ينبغي.<br />إذا نسيت تناول دواء إيزكت<br />لا تتناول جرعتين في آن واحد لتعويضالجرعة المنسية. عليك فقط تناول الجرعة التالية في وقتها المعتاد.<br />إذا توقفت عن تناول دواء إيزكت<br />إذا توقفت عن تناول دواء إيزكت فقد تعاني ارتفاع ضغط الدم مجددا. ولذلك لا تتوقف عن تناول دواء إيزكت دون استشارة طبيبك أولا لمعرفة<br />خيارات العلاج البديلة.<br />في حال كان لديك أي استفسارات أخرى حول استخدام هذا الدواء يرجى توجيهها لطبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثلما الحال مع جميع الأدوية فقد يسبب دواء إيزكت آثارا جانبية علما بأنها لا تحدث لجميع الأشخاص.<br />توقف فورا عن تناول دواء إيزكت، واطلب المساعدة الطبية في حال أحسست بأي من أعراض الحساسية المفرطة التالية وهي نادرة الحدوث<br />(أقل من حالة ١ واحدة في كل ١٠٠٠ شخص):<br />- صعوبة في التنفس أو البلع أو تورم في الوجه أو الشفاه أو اللسان و/أو الحنجرة (وذمة وعائية)<br />- حك جلدي مع نتوءات بارزة.<br />كما تشمل الآثار الجانبية المحتملة الأخرى ما يلي:<br />آثار جانبية شائعة تصيب أقل من حالة ١ واحدة في كل ١٠ شخص:<br />- الدوار<br />- الإسهال<br />- ارتفاع فوسفوكيناس الكرياتين في الدم (وهو مؤشر على تلف العضلات)<br />آثار جانبية غير شائعة تصيب أقل من حالة ١ واحدة في كل ١٠٠ شخص:<br />- ضغط دم منخفض قد يشعرك بالدوار أو الإغماء<br />- الشعور بالتعب<br />- تورم الأيدي أو الكاحلين أو الأقدام (وذمة محيطة)<br />- تهيج وحكة في الجلد<br />- الغثيان<br />- تشنج عضلي<br />- ارتفاع مصل الكرياتينين في الدم (مؤشر على القصور الكلوي)<br />- ارتفاع حمضالبول في الدم (مؤشر على القصور الكلوي)<br />آثار جانبية نادرة تصيب أقل من حالة واحدة من كل ١٠٠٠ شخص:<br />- تغيرات في نتائج فحصالدم من ضمنها انخفاضمستويات البروتين في كرات الدم الحمراء (الهيموغلوبين).<br />عند تناول دواء إيزكت مع دواء كلورتاليدون (قرص مياه) فقد لوحظ وجود مستويات أعلى بشكل شائع لبعض المواد الكيمائية في الدم (مثل<br />الكرياتينين) وهي مؤشرات على أداء وظيفة الكلى (بنسبة أقل من ١ واحد في ١٠ مستخدمين)، كما يشيع أيضا حدوث انخفاضفي ضغط الدم.<br />كما أن أعراض تورم الأيدي أو الكاحلين أو الأقدام (بنسبة أقل من ١ واحد في ١٠ مستخدمين) عند تناول دواء إيزكت مع أملوديبين (مانع قناة<br />الكالسيوم لمعالجة فرط ضغط الدم) تكون أكثر شيوعا منها عند تناوله منفردا (أقل من ١ واحد في كل ١٠٠ مستخدم). كما قد يتكرر هذا الحدث<br />بشكل أكبر عند تناول أملودبين منفردا.<br />الإبلاغ عن الآثار الجانبية:<br />إذا تعرضت لأي آثار جانبية أخبر طبيبك أو الصيدلي بما في ذلك أي آثار جانبية محتملة لم تذكر في هذه النشرة. كما بإمكانك الإبلاغ عن الآثار<br />الجانبية عن طريق المركز الوطني للتيقظ و السلامة الدوائية المشار إليه في أسفل هذه النشرة. وتستطيع المساعدة عند إبلاغك عن الآثار الجانبية<br />على تقديم معلومات أوفى بشأن سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا يخزن في درجة حرارة تزيد على ٣٠ درجة مئوية.<br />احفظه بعيدا عن متناول الأطفال.<br />كما يشير تاريخ انتهاء الصلاحية إلى آخر يوم في .EXP يمنع استخدام دواء إيزكت بعد تاريخ انتهاء صلاحيته المدون على العلبة بجوار كلمة<br />الشهر المذكور.<br />احفظ دواء إيزكت في علبته الأصلية لتحميه من الضوء والرطوبة.<br />لا ينبغي التخلص من الأدوية في مياه الصرف أو مياه النفايات المنزلية. من الأفضل أن تسأل الصيدلي عن طريقة التخلص من الأدوية التي لم<br />تعد تحتاجها. حيث ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>مكونات دواء إيزكت<br />- المادة الفعالة هي أزيلاسارتان ميدوكسوميل (كبوتاسيوم) إما بتركيز ٤٠ ملجم أو ٨٠ ملجم.<br />- المكونات الأخرى تتضمن: مانيتول، حمض الفيوماريك ، هيدروكسيد الصوديوم، هيدروكسي بروبيل سيليلوز، صوديوم<br />كروسكارميلوز، ميكروكريستالين سيليلوز، و ستيرات المغنسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>شكل دواء إيزكت ومحتويات العبوة<br />.&quot; وعلى الجانب الآخر علامة &quot; ٤٠ &quot; أو&quot; ٨٠ &quot;ASL&quot; إيزكت أقراصبيضاء أو قريبة للبياضمنقوش على جانب واحد علامة<br />إيزكت متوفر في عبوة تحتوي على ٢٨ قرص(العبوة تحتوي على ٤ شرائط يحتوي كل واحد منها على ٧ اقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>Batterjee Pharmaceutical Factory<br />Industrial Area-Phase-IV,<br />Jeddah-21443, Kingdom of Saudi Arabia</p><p>المصنع:<br />Takeda Pharmaceutical Company Limited<br />17-85, Jusohonmachi, 2-chome<br />Osaka 532-8686, Japan</p><p>موقع التعبئة والتغليف الأولي:<br />AndersonBrecon Inc.<br />4545 Assembly Drive<br />Rockford IL 61109, USA</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر ٢٠١6
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ezeact 40 mg tablets
Ezeact 80 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ezeact 40 mg tablets
Each tablet contains 40 mg of azilsartan medoxomil (as potassium).
Ezeact 80 mg tablets
Each tablet contains 80 mg of azilsartan medoxomil (as potassium).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets.
Ezeact 40 mg tablets
White to nearly white round tablets, debossed “ASL” on one side and “40” on the other.
Ezeact 80 mg tablets
White to nearly white round tablets, debossed “ASL” on one side and “80” on the other.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ezeact is indicated for the treatment of essential hypertension in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The recommended starting dose is 40 mg once daily. The dose may be increased to a maximum of<br />80 mg once daily for patients whose blood pressure is not adequately controlled at the lower dose.<br />Near-maximal antihypertensive effect is evident at 2 weeks, with maximal effects attained by<br />4 weeks.<br />If blood pressure is not adequately controlled with Ezeact alone, additional blood pressure reduction<br />can be achieved when this treatment is coadministered with other antihypertensive medicinal&nbsp;products, including diuretics (such as chlorthalidone and hydrochlorothiazide) and calcium<br />channel blockers (see sections 4.3, 4.4, 4.5 and 5.1).<br />Special populations<br />Elderly (65 years and over)<br />No initial dose adjustment with Ezeact is necessary in elderly patients (see section 5.2), although<br />consideration can be given to 20 mg as a starting dose in the very elderly (&ge; 75 years), who may be at<br />risk of hypotension.<br />Renal impairment<br />Caution should be exercised in hypertensive patients with severe renal impairment and end stage renal<br />disease as there is no experience of use of Ezeact in these patients (see sections 4.4 and 5.2).<br />Hemodialysis does not remove azilsartan from the systemic circulation.<br />No dose adjustment is required in patients with mild or moderate renal impairment.<br />Hepatic impairment<br />Ezeact has not been studied in patients with severe hepatic impairment and therefore its use is not<br />recommended in this patient group (see sections 4.4 and 5.2).<br />As there is limited experience of use of Ezeact in patients with mild to moderate hepatic impairment<br />close monitoring is recommended and consideration should be given to 20 mg as a starting dose (see<br />section 5.2).<br />Intravascular volume depletion<br />For patients with possible depletion of intravascular volume or salt depletion (e.g. patients with<br />vomiting, diarrhoea or taking high doses of diuretics), Ezeact should be initiated under close medical<br />supervision and consideration can be given to 20 mg as a starting dose (see section 4.4)</p><p>Black population<br />No dose adjustment is required in the black population, although smaller reductions in blood pressure<br />are observed compared with a non-black population (see section 5.1). This generally has been true for<br />other angiotensin II receptor (AT1) antagonists and angiotensin-converting enzyme inhibitors.<br />Consequently, uptitration of Ezeact and concomitant therapy may be needed more frequently for<br />blood pressure control in black patients.<br />Paediatric population<br />The safety and efficacy of Ezeact in children and adolescents aged 0 to &lt; 18 years have not yet been<br />established.<br />No data are available.<br />Method of administration<br />Ezeact is for oral use and may be taken with or without food (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Second and third trimester of pregnancy (see sections 4.4 and 4.6).
- The concomitant use of Ezeact with aliskiren-containing products is contraindicated in patients with
diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73m2) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Activated renin-angiotensin-aldosterone system (RAAS)<br />In patients whose vascular tone and renal function depend predominantly on the activity of the RAAS<br />(e.g. patients with congestive heart failure, severe renal impairment or renal artery stenosis), treatment&nbsp;with medicinal products that affect this system, such as angiotensin-converting enzyme (ACE)<br />inhibitors and angiotensin II receptor antagonists, has been associated with acute hypotension,<br />azotaemia, oliguria or, rarely, acute renal failure. The possibility of similar effects cannot be excluded<br />with Ezeact.<br />Caution should be exercised in hypertensive patients with severe renal impairment, congestive heart<br />failure or renal artery stenosis, as there is no experience of use of Ezeact in these patients (see<br />sections 4.2 and 5.2).<br />Excessive blood pressure decreases in patients with ischaemic cardiomyopathy or ischaemic<br />cerebrovascular disease could result in a myocardial infarction or stroke.<br />Dual blockade of the RAAS<br />There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or<br />aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including<br />acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors,<br />angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).<br />If dual blockade therapy is considered absolutely necessary, this should only occur under specialist<br />supervision and subject to frequent close monitoring of renal function, electrolytes and blood<br />pressure.<br />ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with<br />diabetic nephropathy.<br />Kidney transplantation<br />There is currently no experience on the use of Ezeact in patients who have recently undergone kidney<br />transplantation.<br />Hepatic impairment</p><p>Ezeact has not been studied in patients with severe hepatic impairment and therefore its use is not<br />recommended in this patient group (see sections 4.2 and 5.2).<br />Hypotension in volume- and /or salt-depleted patients<br />In patients with marked volume- and/or salt-depletion (e.g. patients with vomiting, diarrhoea or taking<br />high doses of diuretics) symptomatic hypotension could occur after initiation of treatment with<br />Ezeact. Hypovolemia should be corrected prior to administration of Ezeact, or the treatment should<br />start under close medical supervision, and consideration can be given to a starting dose of 20 mg.<br />Primary hyperaldosteronism<br />Patients with primary hyperaldosteronism generally will not respond to antihypertensive medicinal<br />products acting through inhibition of the RAAS. Therefore, the use of Ezeact is not recommended in<br />these patients.<br />Hyperkalaemia<br />Based on experience with the use of other medicinal products that affect the RAAS, concomitant use<br />of Ezeact with potassium-sparing diuretics, potassium supplements, salt substitutes containing<br />potassium, or other medicinal products that may increase potassium levels (e.g. heparin) may lead to<br />increases in serum potassium in hypertensive patients (see section 4.5). In the elderly, in patients with<br />renal insufficiency, in diabetic patients and/or in patients with other co-morbidities, the risk of<br />hyperkalaemia, which may be fatal, is increased. Monitoring of potassium should be undertaken as<br />appropriate.<br />Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy<br />Special caution is indicated in patients suffering from aortic or mitral valve stenosis, or hypertrophic<br />obstructive cardiomyopathy (HOCM).</p><p>Pregnancy<br />Angiotensin II receptor antagonists should not be initiated during pregnancy. Unless continued<br />angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should<br />be changed to alternative antihypertensive treatments which have an established safety profile for use<br />in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should<br />be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3<br />and 4.6).<br />Lithium<br />As with other angiotensin II receptor antagonists the combination of lithium and Ezeact is not<br />recommended (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant use not recommended<br />Lithium<br />Reversible increases in serum lithium concentrations and toxicity have been reported during<br />concurrent use of lithium and angiotensin-converting enzyme inhibitors. A similar effect may occur<br />with angiotensin II receptor antagonists. Due to the lack of experience with concomitant use of<br />azilsartan medoxomil and lithium, this combination is not recommended. If the combination proves<br />necessary, careful monitoring of serum lithium levels is recommended.<br />Caution required with concomitant use<br />Non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors,<br />acetylsalicylic acid &gt; 3 g/day), and non-selective NSAIDs<br />When angiotensin II receptor antagonists are administered simultaneously with NSAIDs (i.e. selective<br />COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the<br />antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II receptor<br />antagonists and NSAIDs may lead to an increased risk of worsening of renal function and an increase<br />in serum potassium. Therefore, adequate hydration and monitoring of renal function at the beginning<br />of the treatment are recommended.<br />Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other<br />substances that may increase potassium levels<br />Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing<br />potassium, or other medicinal products (e.g. heparin) may increase potassium levels. Monitoring of<br />serum potassium should be undertaken as appropriate (see section 4.4).<br />Additional information</p><p>Clinical trial data has shown that dual blockade of the RAAS through the combined use of<br />ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of<br />adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute<br />renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).<br />No clinically significant interactions have been reported in studies of azilsartan medoxomil or<br />azilsartan given with amlodipine, antacids, chlortalidone, digoxin, fluconazole, glyburide,<br />ketoconazole, metformin, and warfarin.<br />Azilsartan medoxomil is rapidly hydrolysed to the active moiety azilsartan by esterases in the<br />gastrointestinal tract and/or during drug absorption (see section 5.2). In vitro studies indicated that<br />interactions based on esterase inhibition are unlikely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The use of angiotensin II receptor antagonists is not recommended during the first trimester of<br />pregnancy (see section 4.4).<br />The use of angiotensin II receptor antagonists is contraindicated during the second and third trimester<br />of pregnancy (see sections 4.3 and 4.4).<br />There are no data from the use of azilsartan medoxomil in pregnant women. Studies in animals have<br />shown reproductive toxicity (see section 5.3).<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to angiotensin<br />converting enzyme inhibitors during the first trimester of pregnancy has not been conclusive;<br />however, a small increase in risk cannot be excluded. Whilst there are no controlled epidemiological<br />data on the risk with angiotensin II receptor antagonists, similar risks may exist for this class of<br />medicinal products. Unless continued angiotensin II receptor antagonist therapy is considered<br />essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments<br />which have an established safety profile for use in pregnancy. When pregnancy is diagnosed,<br />treatment with angiotensin II receptor antagonists should be stopped immediately and, if appropriate,<br />alternative therapy should be started.<br />Exposure to angiotensin II receptor antagonist therapy during the second and third trimesters is known<br />to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification<br />retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).<br />Should exposure to angiotensin II receptor antagonists have occurred from the second trimester of<br />pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken Angiotensin II receptor antagonists should be closely observed for<br />hypotension (see sections 4.3 and 4.4).<br />Breast-feeding<br />Because no information is available regarding the use of azilsartan medoxomil during breastfeeding,<br />Ezeact is not recommended and alternative treatments with better established safety profiles during<br />breastfeeding are preferable, especially while breast-feeding a newborn or preterm infant.<br />Fertility<br />No data are available on the effect of azilsartan medoxomil on human fertility. Nonclinical studies<br />demonstrated that azilsartan did not appear to affect male or female fertility in the rat (see<br />section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azilsartan medoxomil has no or negligible influence on the ability to drive and use machines.<br />However it should be taken into account that occasionally dizziness or tiredness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Ezeact at doses of 20, 40 or 80 mg has been evaluated for safety in clinical studies in patients treated<br />for up to 56 weeks. In these clinical studies, adverse reactions associated with treatment with Ezeact<br />were mostly mild or moderate, with an overall incidence similar to placebo. The most common<br />adverse reaction was dizziness. The incidence of adverse reactions with this treatment was not&nbsp;affected by gender, age, or race. Adverse reactions were reported at a similar frequency for the Ezeact<br />20 mg dose as with the 40 and 80 mg doses in one placebo controlled study.<br />Tabulated list of adverse reactions<br />Adverse reactions based on pooled data (40 and 80 mg doses) are listed below according to system<br />organ class and preferred terms. These are ranked by frequency, using the following convention: very<br />common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100);<br />rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), including isolated reports. Within each<br />frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>System organ class&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Frequency&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Adverse reaction<br />Nervous system disorders&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Common&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dizziness<br />Vascular disorders&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Uncommon&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Hypotension<br />Gastrointestinal&nbsp;disorders&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Common&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;Diarrhoea<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Uncommon&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;Nausea<br /><br />Skin and subcutaneous tissue<br />disorders&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Uncommon&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Rash, pruritus<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Rare&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Angioedema<br />&nbsp;<br />Musculoskeletal and<br />connective tissue disorders&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Uncommon&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Muscle spasms<br />General disorders and<br />administration site conditions&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Uncommon&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Fatigue<br />Peripheral oedema<br />Investigations&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Common&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Blood creatine phosphokinase increased<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Uncommon&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Blood creatinine increased<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Blood uric acid increased / Hyperuricemia</p><p>&nbsp;</p><p>Description of selected adverse reactions<br />When Ezeact was coadministered with chlorthalidone, the frequencies of blood creatinine<br />increased and hypotension were increased from uncommon to common.<br />When Ezeact was coadministered with amlodipine, the frequency of peripheral oedema was increased<br />from uncommon to common, but was lower than amlodipine alone.<br />Investigations<br />Serum creatinine<br />The incidence of elevations in serum creatinine following treatment with Ezeact was similar to placebo<br />in the randomised placebo-controlled monotherapy studies. Coadministration of Ezeact with diuretics,<br />such as chlortalidone, resulted in a greater incidence of creatinine elevations, an observation consistent<br />with that of other angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors.<br />The elevations in serum creatinine during coadminstiration of Ezeact with diuretics were associated<br />with larger blood pressure reductions compared with a single medicinal product. Many of these<br />elevations were transient or nonprogressive while subjects continued to receive treatment. Following<br />discontinuation of treatment, the majority of the elevations that had not resolved during treatment were<br />reversible, with the creatinine levels of most subjects returning to baseline or near- baseline values.<br />Uric acid<br />Small mean increases of serum uric acid were observed with Ezeact (10.8 &mu;mol/l) compared with<br />placebo (4.3 &mu;mol/l).</p><p>Hemoglobin and hematocrit<br />Small decreases in hemoglobin and hematocrit (mean decreases of approximately 3 g/l and 1 volume<br />percent, respectively) were observed in placebo-controlled monotherapy studies. This effect is also<br />seen with other inhibitors of the RAAS.</p><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It<br />allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare<br />professionals are asked to report any suspected adverse reactions via National Pharmacovigilance<br />and Drug Safety Centre (NPC) listed below:</p><p>&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone:<br />8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website:www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Based on pharmacological considerations, the main manifestation of an overdose is likely to be<br />symptomatic hypotension and dizziness. During controlled clinical studies in healthy subjects,<br />once daily doses up to 320 mg of azilsartan medoxomil were administered for 7 days and were<br />well tolerated.<br />Management<br />If symptomatic hypotension should occur, supportive treatment should be instituted and vital<br />signs monitored.<br />Azilsartan is not removed by dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, angiotensin II<br />antagonists, plain, ATC Code: C09CA09<br />Mechanism of action<br />Azilsartan medoxomil is an orally active prodrug that is rapidly converted to the active moiety,<br />azilsartan, which selectively antagonises the effects of angiotensin II by blocking its binding to the<br />AT1 receptor in multiple tissues (see section 5.2). Angiotensin II is the principal pressor agent of the<br />RAAS, with effects that include vasoconstriction, stimulation of synthesis and release of<br />aldosterone, cardiac stimulation, and renal reabsorption of sodium.<br />Blockade of the AT1 receptor inhibits the negative regulatory feedback of angiotensin II on renin<br />secretion, but the resulting increases in plasma renin activity and angiotensin II circulating levels<br />do not overcome the antihypertensive effect of azilsartan.<br />Essential hypertension<br />In seven double blind controlled studies, a total of 5,941 patients (3,672 given Ezeact, 801 given<br />placebo, and 1,468 given active comparator) were evaluated. Overall, 51% of patients were male<br />and&nbsp;26% were 65 years or older (5% &ge; 75 years); 67% were white and 19% were black.<br />Ezeact was compared with placebo and active comparators in two 6 week randomised, double blind<br />studies. Blood pressure reductions compared with placebo based on 24 hour mean blood pressure by<br />ambulatory blood pressure monitoring (ABPM) and clinic blood pressure measurements at trough<br />are shown in the table below for both studies. Additionally, Ezeact 80 mg resulted in significantly<br />greater reductions in SBP than the highest approved doses of olmesartan medoxomil and valsartan.</p><p>headache and dyslipidemia. For Ezeact, olmesartan medoxomil and valsartan, respectively<br />dizziness was observed at an incidence of 3.0%, 3.3% and 1.8%; headache at 4.8%, 5.5% and<br />7.6% and dyslipidemia at 3.5%, 2.4% and 1.1%.<br />In active-comparator studies with either valsartan or ramipril, the blood-pressure-lowering effect<br />with Ezeact was sustained during long-term treatment. Ezeact had a lower incidence of cough<br />(1.2%) compared with ramipril (8.2%).<br />The antihypertensive effect of azilsartan medoxomil occurred within the first 2 weeks of dosing with<br />the full effect achieved by 4 weeks. The blood pressure lowering effect of azilsartan medoxomil was<br />also maintained throughout the 24 hour dosing interval. The placebo-corrected trough-to-peak ratios<br />for SBP and DBP were approximately 80% or higher.<br />Rebound hypertension was not observed following abrupt cessation of Ezeact therapy after 6<br />months of treatment.<br />No overall differences in safety and effectiveness were observed between elderly patients and<br />younger patients, but greater sensitivity to blood pressure lowering effects in some elderly<br />individuals cannot<br />be ruled out (see section 4.2). As with other angiotensin II receptor antagonists and angiotensin<br />converting enzyme inhibitors the antihypertensive effect was lower in black patients (usually a<br />low- renin population).</p><p>Coadministration of Ezeact 40 and 80 mg with a calcium channel blocker (amlodipine) or a<br />thiazide- type diuretic (chlortalidone) resulted in additional blood pressure reductions compared<br />with the other antihypertensive alone. Dose dependent adverse events including dizziness,</p><p>hypotension and serum creatinine elevations were more frequent with diuretic coadministration<br />compared with Ezeact alone, while hypokalemia was less frequent compared with diuretic alone.<br />Beneficial effects of Ezeact on mortality and cardiovascular morbidity and target organ damage<br />are currently unknown.<br />Effect on cardiac repolarisation<br />A thorough QT/QTc study was conducted to assess the potential of azilsartan medoxomil to prolong<br />the QT/QTc interval in healthy subjects. There was no evidence of QT/QTc prolongation at a dose of<br />320 mg of azilsartan medoxomil.<br />Additional information<br />Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in<br />combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs<br />Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an<br />angiotensin II receptor blocker.<br />ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular<br />disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage.<br />VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.<br />These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes<br />and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as<br />compared to monotherapy was observed. Given their similar pharmacodynamic properties, these<br />results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in<br />patients with diabetic nephropathy.<br />ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints)<br />was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor<br />or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney<br />disease, cardiovascular disease, or both. The study was terminated early because of an increased risk<br />of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the<br />aliskiren group than in the placebo group and adverse events and serious adverse events of interest<br />(hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren<br />group than in the placebo group.<br />Paediatric population<br />The European Medicines Agency has deferred the obligation to submit the results of studies with<br />Ezeact in one or more subsets of the paediatric population in hypertension (see section 4.2 for<br />information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following oral administration, azilsartan medoxomil is rapidly hydrolyzed to the active moiety<br />azilsartan in the gastrointestinal tract and/or during absorption. Based on in vitro studies,<br />carboxymethylenebutenolidase is involved in the hydrolysis in the intestine and liver. In addition,<br />plasma esterases are involved in the hydrolysis of azilsartan medoxomil to azilsartan.<br />Absorption<br />The estimated absolute oral bioavailability of azilsartan medoxomil based on plasma levels of<br />azilsartan is approximately 60%. After oral administration of azilsartan medoxomil, peak plasma<br />concentrations (Cmax) of azilsartan are reached within 1.5 to 3 hours. Food does not affect the<br />bioavailability of azilsartan (see section 4.2).<br />Distribution</p><p>The volume of distribution of azilsartan is approximately 16 litres. Azilsartan is highly bound to<br />plasma proteins (&gt; 99%), mainly serum albumin. Protein binding is constant at azilsartan plasma<br />concentrations well above the range achieved with recommended doses.<br />Biotransformation<br />Azilsartan is metabolised to two primary metabolites. The major metabolite in plasma is formed by<br />O- dealkylation, referred to as metabolite M-II, and the minor metabolite is formed by<br />decarboxylation, referred to as metabolite M-I. Systemic exposures to the major and minor<br />metabolites in humans were approximately 50% and less than 1% that of azilsartan, respectively. M-I<br />and M-II do not contribute<br />to the pharmacologic activity of azilsartan medoxomil. The major enzyme responsible for<br />azilsartan metabolism is CYP2C9.<br />Elimination<br />Following an oral dose of 14C-labelled azilsartan medoxomil, approximately 55% of radioactivity<br />was recovered in faeces and approximately 42% in urine, with 15% of the dose excreted in urine as<br />azilsartan. The elimination half-life of azilsartan is approximately 11 hours and renal clearance is<br />approximately 2.3 ml/min. Steady-state levels of azilsartan are achieved within 5 days and no<br />accumulation in plasma occurs with repeated once-daily dosing.</p><p>Linearity/non-linearity<br />Dose proportionality in exposure was established for azilsartan in the azilsartan medoxomil<br />dose range of 20 mg to 320 mg after single or multiple dosing.<br />Characteristics in specific groups of patients<br />Paediatric population<br />The pharmacokinetics of azilsartan have not been studied in children under 18 years of age.<br />Older people<br />Pharmacokinetics of azilsartan do not differ significantly between young (age range 18-45 years)<br />and elderly (age range 65-85 years) patients.<br />Renal impairment<br />In patients with mild, moderate, and severe renal impairment azilsartan total exposure (AUC) was<br />+30%, +25% and +95% increased. No increase (+5%) was observed in end-stage renal disease<br />patients who were dialysed. However, there is no clinical experience in patients with severe renal<br />impairment or end stage renal disease (see section 4.2). Hemodialysis does not remove azilsartan<br />from the systemic circulation.<br />Hepatic impairment<br />Administration of Ezeact for up to 5 days in subjects with mild (Child-Pugh A) or moderate<br />(Child-Pugh B) hepatic impairment resulted in slight increase in azilsartan exposure (AUC<br />increased by 1.3 to 1.6 fold, see section 4.2). Ezeact has not been studied in patients with severe<br />hepatic impairment.</p><p>Gender<br />Pharmacokinetics of azilsartan do not differ significantly between males and females. No<br />dose adjustment is necessary based on gender.<br />Race<br />Pharmacokinetics of azilsartan do not differ significantly between black and white populations.<br />No dose adjustment is necessary based on race.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In preclinical safety studies, azilsartan medoxomil and M-II, the major human metabolite,<br />were examined for repeated-dose toxicity, reproduction toxicity, mutagenicity and<br />carcinogenicity.<br />In the repeated-dose toxicity studies, doses producing exposure comparable to that in the<br />clinical therapeutic range caused reduced red cell parameters, changes in the kidney and renal<br />haemodynamics, as well as increased serum potassium in normotensive animals. These effects, which<br />were prevented by oral saline supplementation, do not have clinical significance in treatment of<br />hypertension.<br />In rats and dogs, increased plasma renin activity and hypertrophy/hyperplasia of the renal<br />juxtaglomerular cells were observed. These changes, also a class effect of angiotensin converting<br />enzyme inhibitors and other angiotensin II receptor antagonists, do not appear to have clinical<br />significance.<br />Azilsartan and M-II crossed the placenta and were found in the fetuses of pregnant rats and were<br />excreted into the milk of lactating rats. In the reproduction toxicity studies, there were no effects on<br />male or female fertility. There is no evidence of a teratogenic effect, but animal studies indicated<br />some hazardous potential to the postnatal development of the offspring such as lower body weight, a<br />slight delay in physical development (delayed incisor eruption, pinna detachment, eye opening), and<br />higher mortality.<br />Azilsartan and M-II showed no evidence of mutagenicity and relevant clastogenic activity in in vitro<br />studies and no evidence of carcinogenicity in rats and mice.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol (E 421)<br />Fumaric acid (E297)<br />Sodium hydroxide<br />Hydroxypropylcellulose (E 463)<br />Croscarmellose sodium<br />Microcrystalline cellulose (E 460)<br />Magnesium stearate (E 572)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C. Store in the original package in order to protect from<br />light and moisture. Keep out of the reach and sight of children.<br />Do not use Ezeact after the expiry date which is stated on the carton after EXP. The<br />expiry date refers to the last day of the month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum blisters integrated with desiccant.<br />Pack sizes:&nbsp;One blister pack contains either 7 tablets or 14 tablets or 15 tablets.<br />14, 28, 30, 56, 90 or 98 tablets. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Batterjee pharmaceutical factory
Industrial Area-phase-IV,
Jeddah-21443, Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05 /2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>